Cargando…
Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer
Metastatic castrate resistant prostate cancer (mCRPC) is the major cause of death in prostate cancer patients. Even though some options for treatment of mCRPC have been developed, the most effective therapies remain unclear. Thus finding key patient clinical variables related with mCRPC is an import...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130083/ https://www.ncbi.nlm.nih.gov/pubmed/27990267 http://dx.doi.org/10.12688/f1000research.8201.1 |
_version_ | 1782470681815941120 |
---|---|
author | Shiga, Motoki |
author_facet | Shiga, Motoki |
author_sort | Shiga, Motoki |
collection | PubMed |
description | Metastatic castrate resistant prostate cancer (mCRPC) is the major cause of death in prostate cancer patients. Even though some options for treatment of mCRPC have been developed, the most effective therapies remain unclear. Thus finding key patient clinical variables related with mCRPC is an important issue for understanding the disease progression mechanism of mCRPC and clinical decision making for these patients. The Prostate Cancer DREAM Challenge is a crowd-based competition to tackle this essential challenge using new large clinical datasets. This paper proposes an effective procedure for predicting global risks and survival times of these patients, aimed at sub-challenge 1a and 1b of the Prostate Cancer DREAM challenge. The procedure implements a two-step feature selection procedure, which first implements sparse feature selection for numerical clinical variables and statistical hypothesis testing of differences between survival curves caused by categorical clinical variables, and then implements a forward feature selection to narrow the list of informative features. Using Cox’s proportional hazards model with these selected features, this method predicted global risk and survival time of patients using a linear model whose input is a median time computed from the hazard model. The challenge results demonstrated that the proposed procedure outperforms the state of the art model by correctly selecting more informative features on both the global risk prediction and the survival time prediction. |
format | Online Article Text |
id | pubmed-5130083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | F1000Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-51300832016-12-16 Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer Shiga, Motoki F1000Res Method Article Metastatic castrate resistant prostate cancer (mCRPC) is the major cause of death in prostate cancer patients. Even though some options for treatment of mCRPC have been developed, the most effective therapies remain unclear. Thus finding key patient clinical variables related with mCRPC is an important issue for understanding the disease progression mechanism of mCRPC and clinical decision making for these patients. The Prostate Cancer DREAM Challenge is a crowd-based competition to tackle this essential challenge using new large clinical datasets. This paper proposes an effective procedure for predicting global risks and survival times of these patients, aimed at sub-challenge 1a and 1b of the Prostate Cancer DREAM challenge. The procedure implements a two-step feature selection procedure, which first implements sparse feature selection for numerical clinical variables and statistical hypothesis testing of differences between survival curves caused by categorical clinical variables, and then implements a forward feature selection to narrow the list of informative features. Using Cox’s proportional hazards model with these selected features, this method predicted global risk and survival time of patients using a linear model whose input is a median time computed from the hazard model. The challenge results demonstrated that the proposed procedure outperforms the state of the art model by correctly selecting more informative features on both the global risk prediction and the survival time prediction. F1000Research 2016-11-16 /pmc/articles/PMC5130083/ /pubmed/27990267 http://dx.doi.org/10.12688/f1000research.8201.1 Text en Copyright: © 2016 Shiga M http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Method Article Shiga, Motoki Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer |
title | Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer |
title_full | Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer |
title_fullStr | Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer |
title_full_unstemmed | Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer |
title_short | Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer |
title_sort | two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer |
topic | Method Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130083/ https://www.ncbi.nlm.nih.gov/pubmed/27990267 http://dx.doi.org/10.12688/f1000research.8201.1 |
work_keys_str_mv | AT shigamotoki twostepfeatureselectionforpredictingsurvivaltimeofpatientswithmetastaticcastrateresistantprostatecancer |